DIBAC is one of the few bispecific ADC (BsADC) platforms in the world, leading a new wave of ADC innovation. By incorporating two distinct binding moieties in a single therapeutic entity, BsADCs can potentially offer significant advantages over traditional monospecific ADCs and combination therapies. While promising, the complexity of BsADCs introduces new challenges in antibody engineering, stability and manufacturing, setting a high entry barrier. Our innovative DIBAC platform showcases our deep understanding of disease and target biology, along with extensive experience in bispecific antibody engineering and artificial intelligence-empowered target selection and antibody design.

· Duality Innovative Bispecific Antibody Conjugate

· 1 clinical asset

· 2 preclinical assets

· Enhanced tumor selectivity and payload delivery

· Function synergy and pathway cross-talk

· Potential best-in-class and frontline therapy